Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -103.69M | -97.21M | -100.22M | -94.83M | -89.02M |
| Total Depreciation and Amortization | 263.00K | 297.00K | 315.00K | 312.00K | 317.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.25M | 28.09M | 27.03M | 22.96M | 20.06M |
| Change in Net Operating Assets | -1.12M | -2.85M | 2.30M | -2.40M | -4.54M |
| Cash from Operations | -70.30M | -71.67M | -70.58M | -73.96M | -73.19M |
| Capital Expenditure | -158.00K | -158.00K | -181.00K | -44.00K | -44.00K |
| Sale of Property, Plant, and Equipment | 213.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -173.90M | -185.34M | -166.43M | -16.64M | -35.95M |
| Cash from Investing | -173.84M | -185.49M | -166.61M | -16.69M | -36.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 219.33M | 258.58M | 259.70M | 43.13M | 133.17M |
| Repurchase of Common Stock | -249.00K | -249.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -217.00K | -119.00K | -- | -- | -- |
| Cash from Financing | 218.87M | 258.22M | 259.70M | 43.13M | 133.17M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.28M | 1.06M | 22.51M | -47.51M | 23.98M |